A hydrogel microsphere delivery system enables once-monthly exenatide injections for diabetic cats, using a self-cleaving linker to slowly release the GLP-1 drug over weeks.
Once monthly vs dailyHydrogel microsphere technology extends exenatide from daily to monthly injections for diabetic cats
What the researchers found
A hydrogel microsphere delivery system with a self-cleaving β-eliminative linker enables sustained release of exenatide from a single subcutaneous injection, providing once-monthly dosing for feline diabetes treatment.
Why it matters
Feline diabetes is common and typically requires twice-daily insulin injections. A once-monthly GLP-1 treatment could dramatically improve compliance and quality of life for both cats and their owners.
The numbers in context
Bioavailability: 93% ([Gln28]exenatide) vs 52% (exenatide); depot half-life ~40 days vs ~40 min free peptide; dose 10 mcg/kg
How the study worked
Developed hydrogel microspheres covalently attached to exenatide via β-eliminative linkers. Tested pharmacokinetics and glycemic effects after subcutaneous injection in diabetic cats.
Who was studied
Cats (pharmacokinetic study)
What this study cannot tell us
Small sample size. Preliminary pharmacokinetic and efficacy data. Long-term safety of repeated monthly injections not established. Cost comparison with insulin therapy not addressed.
How to read the evidence
Preliminary — proof of concept with small sample; larger studies needed for clinical validation in veterinary practice.
When this study was published
Published in 2020; long-acting GLP-1 formulations for veterinary use continue development.
The bigger picture
This delivery technology has broader implications — the same microsphere-linker platform could extend the duration of other peptide drugs in veterinary and potentially human medicine.
Questions still open
- How does the glycemic control from monthly exenatide compare to twice-daily insulin in cats?
- Could this delivery platform be applied to human GLP-1 drugs?
- What are the injection site reactions from hydrogel microspheres over multiple months?
Common questions
Why is a once-monthly injection important for cat diabetes?
How does the slow-release technology work?
Read the original research
A once-monthly GLP-1 receptor agonist for treatment of diabetic cats.
Domestic animal endocrinology, 70, 106373
Citation
Schneider, E L; Reid, R; Parkes, D G; Lutz, T A; Ashley, G W; Santi, D V. (2020). A once-monthly GLP-1 receptor agonist for treatment of diabetic cats.. Domestic animal endocrinology, 70, 106373. https://doi.org/10.1016/j.domaniend.2019.07.001